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PREFACE 
 
Initiators of the project 
 
The initiators of this project are the Associate Professor Halina Miller-Podraza, University of 
Gothenburg; Department of medical chemistry and cell biology, Food & Health Concept 
Centre (FHCC) and Skånemejerier. The project is based on the work of Halina Miller-
Podraza and her discovery of the plant product PYLOS, active against Helicobacter pylori. 
 
Treatment of sensitive information 
 
The physiological parts of the compounds in the substrate PYLOS will not be discussed, nor 
will the recipes of the used food products from Skånemejerier. The products analyzed will be 
entitled with letters.   
 
Abbreviations 
 
PYLOS is the brand name of a plant substrate active against H. pylori. In this thesis the word 
PYLOS is used for resuming the two components; rosehip and walnut. 
N = Rosehip 
V = Walnut 
FV = Freeze dried walnut extract 
1 
 
ABSTRACT 
 
Gastric and intestinal disorders are common and costly human health problems worldwide. 
Helicobacter pylori are a gram-negative, pathogen bacteria and the most common cause of 
duodenal and gastric ulcer in the stomach the intestinal mucosa. Prolonged infection and 
colonization can lead to chronic gastritis and stomach cancer. H. pylori are present in the 
gastric and intestinal mucosa of half of the world population and a relation between infection 
and low socioeconomic status has been shown. Today the bacterial infection is treated with 
antibiotics and a proton pump inhibitor (e.g. Losec®). The interest in finding an alternative 
way of treating these bacteria is increasing, due to the risk of developing antibiotic resistance 
and high costs for medical drug treatments. Within Swedish research, a natural plant 
substrate, PYLOS, has been developed, which in laboratory tests and a clinical study, has 
been observed to inhibit adhesion and growth of H. pylori in the gastric and intestinal 
mucosa. The intention is to add the components of PYLOS to an existing food product in 
order to produce a functional food product effective against H. pylori infection. 
This master thesis is based on a collaboration project between four Swedish actors; 
University of Gothenburg, Food & Health Concept Centre (FHCC), Skånemejerier and the 
Swedish University of Agriculture Science. The purpose has been to produce a product 
originating from Skånemejerier, but with addition of raw material and extracts of the plant 
substrate PYLOS. Two types of food products were used; juices and fermented milks. The 
activity in the product against H. pylori has been verified with microbiological analyses as 
hemagglutination-inhibition, where anti-adhesion of bacterial lectins to sialic acid-
glycosylated conjugates on the cell surface was tested, as well as analyses of inhibited 
bacterial growth. The effect of the plant substrate was also tested after product heat treatment. 
The results showed that PYLOS effectively inhibits H. pylori in juice products containing 
different fruit mixtures. Juice E, with its unique fruit composition, turned out to be the most 
effective product. Juice E (250 ml) totally inhibited the bacterial adhesion to erythrocytes 
diluted in a volume of 16-32 L and partially (about 50%) diluted in a volume of 32-256 L, 
depending on the bacterial strain tested. The analysis of bacterial anti-growth gave 
confirming results. However, PYLOS had lower inhibition capacity when added to fermented 
milk products. It is known that milk contains free sialylated oligosaccharides and sialylated 
glycoproteins. Theoretically, these can interfere with hemagglutination-inhibition tests. It is 
possible that sialylated milk compounds competed with sialylated saccharides present on 
erythrocytes resulting in a weaker inhibition of hemagglutination.  
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SAMMANFATTNING 
 
Magsår och tarmbesvär hos människa är vanliga och kostsamma hälsoproblem världen över. 
Helicobacter pylori är en gramnegativ, patogen bakterie och den vanligaste orsaken till 
magsår och katarr i mag- och tarmslemhinnan. Långvarig infektion och kolonisering kan leda 
till kronisk magsjukdom och magcancer. H. pylori finns närvarande i mag- och 
tarmslemhinnan hos halva jordens befolkning och ett samband mellan infektion och låg 
socioekonomisk status har påvisats. Idag behandlas denna bakterieinfektion med antibiotika 
och en protonpumpshämmare (t.ex. Losec®). P.g.a. risker för antibiotisk resistensutveckling 
och höga läkemedelskostnader är intresset stort att finna ett alternativt sätt att behandla 
bakterieinfektionen. Inom svensk forskning har ett naturligt växtextrakt, PYLOS tagits fram, 
som i laborativa analyser och i klinisk studie visat sig hämma adhesion och tillväxt av H. 
pylori i mag- och tarmslemhinnan. Målet med PYLOS är att integrera substratet i ett 
existerande livsmedel och därigenom skapa ett mervärde, ett livsmedel med egenskaper 
aktiva mot H. pylori.  
Detta examensarbete bygger på ett samarbetsprojekt mellan fyra svenska aktörer; Göteborgs 
Universitet, Food & Health Concept Centre (FHCC), Skånemejerier och Sveriges 
lantbruksuniversitet. Syftet har varit att genom produktutveckling ta fram en produkt med 
ursprung från Skånemejeriers sortiment som är lämplig för tillsats av växtextraktet PYLOS. 
Aktiviteten mot H. pylori hos de framtagna produkterna verifierades genom mikrobiologiska 
analyser som inhiberad tillväxt samt hemagglutination; där bakteriens anti-adhesion till 
sialinsyra-glykosylerade konjugat på cellens yta testades. 
Två typer av livsmedel användes för detta ändamål; juicer och fermenterade mjölkprodukter. 
Råvaran till PYLOS och dess extrakt jämfördes, liksom PYLOS bevarade aktivitet efter att 
produkterna genomgått en värmebehandling. 
Resultat visade att PYLOS effektivt inhiberar H. pylori i olika juiceprodukter och bäst 
resultat visade juicer innehållande kombinationen av två specifika frukter. Juice E om 250 ml 
innehållande en maximal koncentration av PYLOS, hämmade till 100% adhesionen av 
bakterien utspädd till en volym om 16-32 L. Adhesionen hämmades partiellt (ned till 50%) av 
produkten utspädd till en volym om 32-256 L. Tester av H. pylori anti-tillväxt gav 
överensstämmande resultat. PYLOS uppvisade sämre hämningsförmåga tillsatt i 
fermenterade mjölkprodukter. Det är känt att mjölk innehåller sialylerade oligosackarider och 
sialylerade glykoproteiner, vilka teoretiskt skulle kunna störa hemagglutinationshämmande 
tester. Det är möjligt att sialylerade mjölkföreningar konkurrerat med sialylerade sackarider 
som finns på erytrocyter, vilket vid analysförfarandet lett till svagare hämning av 
hemagglutination.  
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1. INTRODUCTION 
1.1. Helicobacter pylori 
1.1.1. The bacterial characteristics and colonization in humans 
 
Former theories stated that gastrointestinal diseases and ulcer was a result of stress and 
psychological unhealthy lifestyle. Twenty years ago, revolutionizing research reported that 
the symptoms caused by chronic gastritis, instead could be occasions of a bacterial infection. 
The discovery rendered the Nobel Prize in medicine in 2005 and since then, the scientific 
knowledge about Helicobacter pylori has grown remarkably (Arnqvist & Borén, 2003). 
H. pylori cause one of the most common bacterial infections in the world. Half of the world 
population is thought to be carrier of the bacteria and about 33% of the Swedish population 
(Arnqvist & Borén, 2003). H. pylori is a 2-4 µl long, microaerophilic, spiral, flagellated and 
urease positive bacteria (Lin, et al., 2005). It is physiological designed for its mobility and its 
ability to colonization in the mucus environment. 
1.1.2. The gastro duodenal disease 
 
An established infection causes inflammation in the gastric mucosa, called gastric catarrh. 
Some patients develop gastric ulcers in both the stomach and the duodenum (Arnqvist & 
Borén, 2003). Most of the carriers of the H. pylori bacteria have a mild chronic and 
asymptomatic inflammation, which does not require medical treatment. But 10-20% of the H. 
pylori infected individuals develop gastric diseases, with digestive syndromes like chronic 
inflammations and duodenal and gastric ulcer. Over 90% of all ulcer patients have infections 
caused by H. pylori. An infection is often life long without treatment and the probability to 
get symptoms increases with time exposed to the pathogenic cells.  
H. pylori colonize naturally as a result of human contact with microbes. A relationship 
between socioeconomic standard and bacterial infection has been proven. Today the bacteria 
are usually common in developing countries, while a marked decline has been noticed in the 
industrialized part of the world (Marshall, 2002). H. pylori gastric colonization is known to 
start early in life. The mother or other family members are the most common sources of 
infection of small children, living in unsanitary conditions, without running water (Marshall, 
2002). The bacteria spreads by the fecal-oral rout and possibly also the oral-oral route and by 
contaminated areas. Lower infection rate in industrialized countries are thought to be a result 
of improved sanity conditions, housing with fewer individuals and the increased use of 
antibiotics during childhood (Cover & Blaser, 2009). H. pylori have been classified by WHO 
(World health organization) as type 1-carcinogenic and are proved to cause stomach cancer in 
about 1-3% of the H. pylori positive patients (Miller-Podraza, et al., 1997). In developing 
countries, gastric cancer is one of the most common forms of cancer (Marshall, 2002). 
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1.1.3. Biological factors that promote coexistence 
 
There are several factors that enable existents of the bacteria in the stomach. The most 
important may be the H. pylori production of the enzyme ureas which can degrade the 
substance of urea. During such degradation, carbon dioxide and the basic compound 
ammonia are produced (Arnqvist & Borén, 2003). The ammonia is transformed to 
ammonium in presents of water and the remaining hydroxyl ion reacts with carbon dioxide, 
making bicarbonate which neutralizes gastric acid and makes the stomach environment 
survivable (Arnqvist & Borén, 2003). 
Factors that also contributes to the coexistence is the location of the H. pylori in the mucus 
layer without substantial invasions of host tissue and its production of components that are 
adapted to reduce the human host immune response. One of those compounds is the special 
lipopolysaccharide (LPS), which with modifications of one lipid residue (cholesterol) makes 
the inflammation less intense. The bacteria is also capable of visualize itself as the adhesion 
molecules on the host cell to avoid the immune system to react, similar to the expression of 
the LPO 0 antigens that are structurally related to Lewis blood group antigen found in human 
cells. After infected the area, H. pylori are usually the dominant microorganism in the gastric 
region. It does have mechanisms to obtain valuable nutrients and produces peptides that 
reduce the competition from other microbes in the stomach. (Cover & Blaser, 2009) 
1.1.4. The attachment to the cell 
 
There are strain variations in how H. pylori are attached to the gastric epithelial cell surface. 
H. pylori have outer membrane proteins on its surface that function as adhesins; binding to 
membrane-associated lipids and carbohydrates. Several carbohydrate epitopes have been 
mentioned in the description of the adhesion of H. pylori to the cell surface receptors. These 
are called BabA, which binds to the fucoslylated Lewis b receptor displayed on the surface of 
the gastric epithelial cells and SabA, which binds to sialyl Lewis X receptors containing 
structures of sialyl acid (Cover & Blaser, 2009). Selected sialylated structures (containing N-
acetylneuraminic acid) is said to be some of the most important adhesion factors (Miller-
Podraza, 2009). These adhesion proteins are covered by the lipopolysaccharide molecule 0 
(LPS 0) which structure is the same as Lewis blood group antigen, which makes human 
belong to blood group 0 according to the AB0-system. These similar systems with a modified 
cholesterol molecule could make the body to recognize H. pylori LPS as a component of its 
own (Cover & Blaser, 2009). According to Arnqvist and Borén (2002), this circumstances 
promotes the theory that people with blood group 0 is at greater risk of encounter the 
infection of H. pylori, due to the similar appearance of the sugar structures, where H. pylori 
could affect the immune system not to respond on the foreign bacteria.  
1.1.5. Potential beneficial properties 
 
H. pylori have also been associated with some beneficial properties in the body. Presence of 
H. pylori has been related with increased protection of allergy- induced asthma. Allergy 
scientists from Universities of Zurich and Gothenburg have in animal studies stated that the 
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increased level of asthma in industrial societies could be related to enhance of hygienically 
secured environments and the decreased infection rate of H. pylori. The bacteria have also 
been reported to counteract acid reflux disease due to the production of ammonium and 
bicarbonate in the stomach. (Arnold, et al., 2011) 
1.1.6. Clinical treatments used today 
 
The treatment of H. pylori infected patients is based on the medical drug Losec®, an inhibitor 
of the proton pump that decreases the production of acid in the stomach. Losec® is consumed 
in combination with two different antibiotics during one week (Arnqvist & Borén, 2003). The 
risk for re-infection is low; about 0.5-2% of the treated patients gets re-infected per year. The 
practical issue of giving antibiotics to all infected patients is impossible, partly because of the 
heavy hypothetical cost, but also due to the increased risk of bacterial resistance. The use of 
antibiotics has resulted in a decreasing trend of peptic ulcer diseases, but it has also resulted 
in increased H. pylori resistance to some of the most used antibiotics (Cover & Blaser, 2009).  
Escalating resistance decreases the efficacy of the medical treatment and the pharmaceutical 
industry now calls for new alternative methods to treat the bacteria.  
1.2. PYLOS 
1.2.1. The project  
 
The PYLOS-project started in 2006 as collaboration between the Associate Professor Halina 
Miller-Podraza at the Department of medical chemistry and cell biology at University of 
Gothenburg, Food & Health Concept Centre (FHCC) and Skånemejerier.  
PYLOS is a natural plant substrate inhibiting H. pylori and preventing peptic ulcer diseases 
and in the extension, the development of digestive cancer. PYLOS has anti-adhesion 
properties based on the inhibition of the carbohydrate binding proteins, lectins, of H. pylori 
which bind to the glycoconjugates on the cell surface. Its anti-adhesion agents are chemically 
related to the epitopes on the target cells and restrain the binding of H. pylori (Miller-
Podraza, 2009). PYLOS does also inhibit the bacterial growth and decreases the risk of 
inflammatory proliferation. The purpose of the product is to help people suffering from peptic 
ulcer to improve their digestive health, decrease the widespread use of antibiotics and 
contribute to a positive development of public health using natural ingredients. The natural 
ingredients are available on the market today which enables the option that people without 
digestive problems also will be able to consume the product. The vision of PYLOS is to be a 
respectful and leading actor within the field of inhibiting H. pylori (Food & Health Concept 
Centre, 2011). 
1.2.2. The active components 
 
Studies have shown that several plants contain a wide range of active compounds with ability 
to inhibit both growth and adhesion of H. pylori. PYLOS is the brand name of a specific 
mixture of rosehip and walnut powder/extract, scientifically proven to prevent the growth and 
attachment of H. pylori in the stomach lining (Miller-Podraza, 2009).  
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The compound/s exhibiting the inhibitory activity against H. pylori is thought to be 
polyphenoles, other antioxidants or proteins. Antimicrobial activities in key phenolic 
phytochemicals in plants have been detected in earlier studies (Lin, et al., 2005). Both rosehip 
and walnut shows activity against bacterial adhesion to sialic acid and growth of H. pylori, 
but both have special effects. Rosehip is known to mainly have anti-adhesion properties, one 
gram dried fruit has 100% inhibition of binding to sialic acid in the volume of 200 ml and 
partial inhibition in the volume of 400-800 ml. Walnut is better known for its inhibition of H. 
pylori-growth and has 100% inhibition in 40 ml and partial inhibition in 80-160 ml (Miller-
Podraza, 2009). A number of other plants, fruits and berries have also been shown to have 
similar properties against the bacteria. An important aspect is their ability to complete and 
strengthen each other’s inhibitory activities (Miller-Podraza, 2009). 
Rosehip and walnut has earlier been investigated through treatment in different conditions. 
Those studies have shown that the activity of both plants are stable at low pH-environment 
(pH 1), but are sensitive for heat-treatment at higher temperatures (75°C for more than 30 s). 
Walnut is more sensitive than rosehip. (Miller-Podraza, 2011) 
1.2.3. Clinical in vivo study   
 
A pilot study on human was performed by Food & Health Concept Centre during year 2010-
2011, where a combination of walnut and rosehip extract was given to H. pylori positive 
patients to confirm the same inhibiting effect in vivo as was proven in vitro.  
In the study, 182 volunteers were tested for H. pylori infection. Only 14 persons showed a 
positive result in a test of antibody response through blood specimen collection and an urea 
breath test. The low infection frequency could be explained by the common use of antibiotics 
in our society. A treatment of antibiotics once in life means that a potential earlier H. pylori 
infection could have been cured. Eleven persons participated in the pilot study, where the 
hypothesis investigated was that PYLOS could prevent the bacterial attachment to the 
stomach lining and hinders further growth. Of these eleven persons, seven were females and 
four were men. None of the patients had earlier awareness of their H. pylori infection and 
none have had symptoms related to it. The patients were given 8 g rosehip and 8 g walnut 
powder twice-a-day during 30 days. After 30 days of treatment, the effect was shown in an 
exhalation test, where urea was measured. Of the eleven persons treated, 73% (8 of 11) had 
on average halved their amount of H. pylori. Two persons (18%) were shown to be free from 
the H. pylori-infection and one person did not respond to the treatment. (Björkman, 2011) 
1.2.4. Functional foods  
PYLOS as food ingredients and dietary supplements are planned for health concept food 
stores and pharmacies. The consumers of today are anxious of their health and the demand of 
products with added values increases. Functional foods are food with scientifically proven 
active ingredients that has beneficial physiological effects in the body, beyond the ordinary 
nutritional values (Blücher, 2003). The product could be an innovation, but is often an 
improvement of an already existing product on the market, with valuable additives and a 
health-promotion. Functional foods are considered as product on the boundary between foods 
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and medicine. The foods are a part of a strong global health trend with strong drive in USA 
and Europe. Qualified functional foods is a good alternative for the society and the individual 
to prevent diseases that originates in the industrialized part of world, like high blood pressure, 
problems with digestive health, diabetes and obesity (Bruce, 2000). A good market potential 
can be expected for functional food products. The market is growing with about 10-20% per 
year with a continued increasing demand (Food & Health Concept Centre, 2011). 
2. AIM 
 
The purpose with this master thesis has been to develop a product, originating from the range 
of Skånemejerier but with addition of the plant substrate PYLOS, and evaluate the activity 
against H. pylori using verifying microbiological analyses. 
The study is based on following question formulation; 
How is the activity of PYLOS against H. pylori affected after addition to different liquid food 
products? 
 
3. MATERIAL & METHODS 
 
3.1. Study design 
 
The study was divided in two parts. The first part involved product development, where 
PYLOS was added to already existing products of Skånemejerier and taste, consistency, color 
etc. were evaluated in a descriptive sensory test. Small batches of 16 products with four 
different concentrations of PYLOS were produced. In the second part, the inhibition activity 
of the new products were tested against H. pylori with verifying microbiological analyze 
methods at University of Gothenburg.   
3.2. Materials 
3.2.1. The PYLOS substrate 
 
Particular requirements were requested for the raw material; rosehip (Rosa canina) and 
walnut (Juglans regia), which were carefully selected from specific suppliers. Walnut 
powder contains large particles with all natural components included. The walnut powder has 
also been compared with freeze dried walnut powder extract. The extract, is walnut powder 
extracted with water and freeze dried. This report will in the following mention the use of 
PYLOS substrate as rosehip and walnut (N+V) in weight relationship 1:1 respectively 
rosehip and freeze dried walnut extract (N+FV) in weight relationship 1:0.2. The two 
combinations were used in different products. FV had a higher activity/g than V and was 
therefore used in lower amount, 1 g V = 0.2 g FV (Miller-Podraza, 2011). 
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3.2.2. Juice concentrates 
 
The juice products A, B, C, D, E and F were all specific beverages containing fruit 
concentrates with different components. The juices were natural products, containing 100% 
fruits and no added sugar, produced at the dairy of Skånemejerier.  
3.2.3. Fermented milk products 
 
The products G, H, I and J were fermented milks with 0.5-1% fat. The products were 
fermented using different starter cultures which resulted in unique characters in terms of taste 
and texture. The fermented milk products were all chosen with low amount of fat, to avoid 
too thick texture when adding PYLOS.  
 
3.3. Experiments and analyses 
3.3.1. Product development 
 
The product development procedure was done as a small-scale sensory test in the lab of 
product development at Skånemejerier, Lunnarp. Small batches of 250 ml were produced 
through mixing fruit concentrate with water to right concentrations, following the guideline 
of Skånemejerier, and adding substrate of PYLOS in four different concentrations. Fermented 
milk products with PYLOS added, were also developed.  
According to the clinical in vivo study, 8 g rosehip and 8 g walnut twice-a-day had positive 
effects against H. pylori in infected patients (Björkman, 2011). 16 g rosehip and 16 g walnut 
was therefore used as the maximal dose of PYLOS substrate in the products produced. To 
analyze the optimal activity level of PYLOS, the concentration of substrate was also added as 
divided to the half (8 g + 8 g), a quarter (4 g + 4 g) and an eighth parts (2 g + 2 g) of the 
maximal dose for every product (Table 1). 
Addition of PYLOS substrate was done in both juices and the fermented milk products. In the 
juice samples, walnut was added both as powder (V) and as freeze dried walnut extract (FV). 
However, the FV was difficult to solve and therefore the juice product C was warmed to 
48°C in order to increase the solubility.  
Sensory tests 
The sensory test was performed as a descriptive Free Choice Profiling test. In a Free Choice 
Profiling test, each assessor creates his/her own attributes for the product and no panel 
training needs to be done (Lawless & Heymann, 2010). The assessors were allowed to 
evaluate the product in different ways and the data was then summarized. The assessors used 
were an internal panel of three people at the product development unit of Skånemejerier. The 
panel was presented samples of products with four different concentrations of PYLOS, asked 
to choose in which concentration of PYLOS the product was acceptable. Acceptable meant in 
this study that the product tasted good, looked good or represented any other positive opinion 
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including greater satisfaction. The panel was also asked to answer which flavors that were 
prominent and less prominent in the different concentrations and in which degree the 
products tasted bitter on a 1-4 degree scale. The tested samples are shown in Table 1. These 
samples were then analyzed for activity against H. pylori in the verifying microbiological 
tests. 
Table 1 Produced samples of juices and fermented products with PYLOS substrate added 
Products PYLOS 
substrate 
PYOS (g) 
/250ml 
PYLOS (g) 
/250ml 
 PYLOS (g) 
/250ml 
PYLOS (g) 
/250ml 
Juice A-F N+V 16+16 8+8 4+4 2+2 
Juice A-E N+FV 16+3.2 8+1.6 4+0.8 2+0.4 
Fermented milk G-J N+V 16+16 8+8 4+4 2+2 
 
3.3.2. Verifying microbiological analyses 
 
The microbiological analyses were divided in two analytical methods to study different 
inhibition mechanisms of PYLOS.  
1.) A hemagglutination test was performed to investigate the inhibition effect of the PYLOS 
product against the adhesion of H. pylori to human erythrocytes through interactions with 
membrane bound sialylated carbohydrate structures. Inhibition of agglutination was evaluated 
using light microscopy (Miller-Podraza, et al., 1997).  
2). A growth inhibition test on agar plates was performed to detect anti-growth properties of 
the PYLOS products.  
Before analysis the products was filtrated, in purpose to eliminate lumps and to get a thinner 
consistency. The product was warmed at room temperature and shaken. The sample was 
filtered with filter paper grade 113 µm (Whatman, Buckinghamshire, UK) under vacuum 
pressure.  
1). Hemagglutination inhibition assay 
The hemagglutination inhibition tests were started by separating the human erythrocytes from 
a fresh human blood sample (blood type 0) through washing with Phosphate-Buffered Saline 
(PBS). The sample was centrifuged 3 times at 1.5 rpm during 6 min discarding the 
supernatant.  
Culture tissue plates with 96 wells (Sarstedt AB, Germany) were used in the analyses (follow 
the method in Table 2). The first row, A1-A12, was used as H. pylori-controls wells where 
A1-A6 was negative controls (H. pylori not included) and A7-A12 were positive controls (H. 
pylori included). 38 µl PBS was added in the negative control and 25 µl PBS was added in 
the positive control. The wells B1-H12 were filled with 25 µl PBS. In well C1-H1 the 
filtrated product containing PYLOS was added in a volume of 50 µl and mixed with the PBS. 
The products were compared with a PYLOS-control (B1-B12), wells with 50 µl of N+V or 
N+FV due to the content of the investigated product. The products and the PYLOS-control 
were then diluted two-folded by transferring 25 µl from B1-H1 to B2-H2 and mixing. Then 
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25 µl was taken from B2-H2 and transferred to B3-H3 and was mixed, etc. until a dilution of 
2058 was reached in every row (Table 2). The plate was incubated for 0.5-1 hour at room 
temperature. After incubation, 50 µl of the erythrocytes was diluted with 5 ml PBS to a 
concentration of 1% and 25 µl of the solution was added to all wells. One colony of H. pylori 
was diluted in 11 ml PBS and 12.5 µl of the solution was added in all wells but the negative 
control. The plate was incubated at room temperature for 1.5-2 hours. The same procedure 
was done with all the products.  
Table 2 The table illustrates the culture tissue plate in which the hemagglutination assay was performed    
2-fold dilution 
Dilution 0 2 4 8 16 32 64 128 256 512 1024 2058 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
A C.1 Ery.2 PBS + Ery2 PBS + Ery2 + H. pylori 
B C.1 PYLOS            
C Product 1            
D Product 1            
E Product 2            
F Product 2            
G Product 3            
H Product 3            
1 C. = Control, 2Ery. = Erythrocytes 
Every product was analyzed twice. Two different strains of H. pylori were used in every test 
to increase the reliability of the results. H. pylori CCUG 17874 was used in all experiment as 
a standard strain. In addition another strain, J99, was used to verify the result. Both strains 
came from the culture collection of University of Gothenburg.  
The reaction was observed through examination a small volume from every well in the 
microscope. When the bacteria attached to the cell, agglutination occurred that was seen as 
big aggregated flaks of erythrocytes. When the product including PYLOS was added, the 
agglutination was inhibited and the bacteria did not attach to the cell. Only free erythrocytes 
observed in the microscope indicated complete inhibition of agglutination; the inhibiting 
product was said to work anti-adhesive.  No free erythrocytes observed, indicated total 
agglutination; the inhibiting product was diluted to a rate where it was no longer effective. 
Table 3 shows an example of a reaction evaluation of a culture tissue plate using the 
microscope. The rate of agglutination was subjectively estimated and graded at a 4-degree 
scale illustrated with pluses, where “-“ meant no agglutination (100% inhibition) and “++++” 
meant full agglutination (0% inhibition). About 50% inhibition was illustrated with “++”. 
This method showed in which volume the products with PYLOS inhibited H. pylori adhesion 
with 100%, 50% and 0%.  
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Table 3 The table shows an example of an evaluation of a culture tissue plate when grading the rate of agglutination in the 
microscope 
2-fold dilution 
Dilution 0 2 4 8 16 32 64 128 256 512 1024 2058 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
A C.1 Ery.2 - - - - - ++++ ++++ ++++ ++++ ++++ ++++ 
B C.1 PYLOS - - - - -/+ + ++ +++ ++++ ++++ ++++ 
C Prod3 max4 - - - + ++ +++ ++++ ++++ ++++ ++++ ++++ 
D Prod3 max4 - - - + ++ +++ ++++ ++++ ++++ ++++ ++++ 
E Prod3 med5 - - + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ 
F Prod3 med5 - - -/+ ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ 
G Prod3 min6 - -/+ ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
H Prod3 min6 - + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
1 C. = Control, 2Ery. = Erythrocytes, 3Prod. = Product, 4Max = Maximal concentration, 5Med = Medium concentration,  
6Min = Minimal concentration, “-“ = No agglutination (100% inhibition), “+” = Weak agglutination, “++” = Partial 
agglutination (50% inhibition), “+++” = Strong agglutination, “++++” = Total agglutination, (no inhibition) 
2). Growth assay  
The growth inhibition tests of H. pylori were done using 3 ml agar-gel on agar plates, 3.5 cm 
in diameter (Sarstedt AB).  The inhibitory product was filtrated through sterile filters 
(filtropur S-plus, 0.2 µm, Sarstedt AB), to avoid bacterial growth which could compete with 
H. pylori. The PYLOS product was diluted to 1:1 and 1:2 and applied in a volume of 200 µl 
on the surface of the agar plates and the product was allowed to sink into the gel overnight. A 
plate applied with water (200 µl) made the control sample for the bacterial growth and an 
addition of N+V/N+FV (200 µl) was the inhibition control. The H. pylori cells were streaked 
on the agar plate and the bacteria were allowed to grow for two days at 37°C. If inhibition 
appeared after two days, further dilutions of the product were tested (i.e. 1:4 and 1:8) to 
determine at which dilution the inhibition effect disappeared.  
Table 4 shows an example of how the agar plates were analyzed after incubation. The results 
were read in the same way as in the hemagglutination assay. The rate of growth was 
subjectively estimated and graded at a 4-degree scale illustrated with pluses, where “-“ meant 
no growth (100% inhibition) and “++++” meant full growth (0% inhibition). About 50% 
inhibition was illustrated with “++”. This method showed in which volume the products with 
PYLOS inhibited H. Pylori growth with 100%, 50% and 0% efficiency. The growth assay 
was performed on a limited number of products, only products with maximal concentrations. 
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Table 4 The table shows an example of an evaluation of grading the rate of growth on agar-plates 
2-fold dilution 
Dilution 0 2 4 8 16 32 64 128 256 512 1024 2058 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
A C.1 Ery.2 - - - - - ++++ ++++ ++++ ++++ ++++ ++++ 
B C.1 PYLOS - - - - -/+ + ++ +++ ++++ ++++ ++++ 
C Prod3 max4 - - + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ 
D Prod3 max4 - - + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ 
E Prod3 med5 - + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
F Prod3 med5 - -/+ ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
G Prod3 min6 + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
H Prod3 min6 + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
1 C. = Control, 2Ery. = Erythrocytes, 3Prod. = Product, 4Max = Maximal concentration, 5Med = Medium concentration,  
6Min = Minimal concentration, “-“= No growth (100% inhibition), “+” = Weak growth, “++” = Partial growth (50% 
inhibition), “+++” = Strong growth, “++++” = Total growth, (no inhibition) 
Treatment of controls 
The controls used were extracts of N+V with concentration ratio 1:1 and N+FV with 
concentration ratio 1:0.2 for products including N+V and N+FV, respectively. The controls 
were made by making dilutions in water of N, V and FV. The controls were shaken and kept 
overnight before filtrated. The same controls were used for all products and were kept in a 
freezer when not used. New bacterial colonies were used every day and since the quality and 
agglutination strength of H. pylori could vary, a control analyze was performed with every 
new bacterial colony used. The controls of PYLOS had a higher concentration than in the 
product and were therefore adjusted with a regulation factor to correspond to the 
concentration of PYLOS in the products (Mathematical models). 
Investigative tests of fermented milk products 
During the experimental period, an obvious decrease of the inhibition activity of PYLOS was 
observed in the fermented milk products. Several investigative tests were performed to study 
where in the process the activity was lost. Only H. pylori strain CCUG 17874 was used in 
these tests, which are summarized in Table 5.  
To eliminate the option that the product had not been produced properly, new samples with 
PYLOS substrate added to product H were made. Different filtration methods were used to 
see if any technical factor was responsible for the loss of activity. The filter paper was 
changed; a large amount of substrate could have been lost during the filtrating process. The 
product was also extracted by dilution and centrifugation. Different concentrations of PYLOS 
were tested to determine if the amount of substrate was important for the preservation of 
activity. The incubation times were also varied, during which the mixture was shaken before 
filtration. Samples were also mixed with erythrocytes to exclude the option that the milk 
itself may agglutinate the erythrocytes. In one test hydrochloric acid (HCl) was added to a 
sample to denature the milk proteins further. The sample was centrifuged and the proteins 
were discarded before the sample was neutralized with sodium hydroxide (NaOH) and 
analyzed with hemagglutination. Sodium chloride (NaCl) was also added to a sample before 
analyze to eliminate the option that osmosis affected the erythrocytes in the previous test 
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(HCl + NaOH  NaCl + H2O). All tests were performed using product H with maximal 
concentration of PYLOS. The control used in these tests was the origin product H with 
maximal concentration of PYLOS. 
Table 5 Following tests were done to investigate the loss of activity in the fermented milk products  
Test Method 
 
New mixture PYLOS was mixed with product H once more to make sure that the mixture 
was done properly. 
Filter paper Filter paper 113 µm (Whatman) was used in the filtration procedure. 
 
Filter paper Filter paper (thin) (Whatman) was used in the filtration procedure 
 
Filter paper Filter paper (thick) (Whatman) was used in the filtration procedure. 
 
Centrifugation Centrifugation was used instead of filtration (3 x 4.0 rpm) 
 
Dilution The product was diluted 2 times and incubated during 4 h, before filtration 
with a thin filter paper. 
Dilution The product was diluted 2 times and incubated over night before filtration 
with a thin filter paper. 
No filtration The product was not filtrated at all before analyze. 
 
Change of conc7 32 g PYLOS (1:1) was mixed with 250 ml product and incubated during 5 h 
before analyze. 
Change of conc7 16 g PYLOS (1:1) was mixed with 250 ml product and 16 ml PBS and 
incubated during 5 h before analyze. 
Change of conc7 8 g PYLOS (1:1) was mixed with 250 ml product and 25 ml PBS and 
incubated during 5 h before analyze. 
Change of inc9 time 32 g PYLOS (1:1) was mixed with 250 ml product. 10 ml was incubated 
during 0.5 h before analyze. 
Change of inc9 time 10 ml of the product above was incubated during 4 h before analyze. 
 
Change of inc9 time 10 ml of the product above was incubated over night before analyze. 
 
Sample + Ery2 Erythrocytes were added to the product without H. pylori. 
 
HCl added 3 M HCl was added to the product filtrate to reach pH 1. The product was 
centrifuged and proteins removed. 3 M NaOH was added to reach pH 4.5.    
NaCl + Ery2 + Hp8 3 M NaCl was added to erythrocytes and H. pylori. 
2Ery = Erythrocytes, 7Conc. = Concentration, 8Hp = H. pylori, 9Inc. = Incubation  
Heat treatment 
When producing fermented milk, the milk is heat treated at 95°C for about 10 min before 
addition of lactic acid bacteria. Juice products are also pasteurized at 90°C for 10 s before 
packaging. When adding PYLOS to a food product, it has to be sure that even the PYLOS 
substrate is free from pathogenic bacteria and therefore it would be an advantage if PYLOS 
could be added to the product before the heat treatment. A heat treatment test was thus done 
to find out how the inhibition of H. pylori was affected by heating PYLOS.  
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Heat treatment was done in small scale using a waterbath on an induction cooker. The 
induction regulation made it easy to adjust the temperature, which was controlled by a 
thermometer. The juice C with PYLOS substrate N+V (16 g + 16 g) and N+FV (16 g + 3.2 g) 
and milk (0.5% fat) with PYLOS substrate N+V (16 g + 16 g) and N+FV (16 g + 3.2 g), were 
heated in eppendorf-tubes in waterbath. The temperature and time used was adapted to 
standard heat treatment procedures at the dairy; i.e. low pasteurization (72°C for 15 s), high 
pasteurization (85°C for 5 s) and heat treatment of milk which will be fermented (95°C for 10 
min) (Walstra, et al., 2006). The samples were placed on icebath after heating. The juices 
were pasteurized at 90°C for 10 s in accordance with the procedure of Skånemejerier. The 
control used in this test was the same product, not heat treated. 
 
3.4. Mathematical models 
3.4.1. Verifying microbiological analyses 
 
The inhibition effect of PYLOS by volume 
Since the target of the product is the stomach, it is important to know at which volume the 
product is inhibitive. Table 6 shows an example of an evaluation of a hemagglutination assay. 
The concentrations of rosehip and walnut substrate have been considered as the concentration 
of PYLOS (N+V or N+FV), to simplify the calculations and to visualize that the two 
substrates are acting together against H. pylori.  
 
The effect of PYLOS has been calculated as the following example: 
A product with maximal concentration:  
16 g (N) + 16 g (V) in 250 ml = 32 g PYLOS in 250 ml. 
32 g / 250 ml = 1 g / 7.81 ml  
 
100% inhibition ended in a dilution up to 4 times (Table 6).  
4 x 7.81 = 31.25 ml  1 g PYLOS was effective in 31.25 ml 
32 g PYLOS used gives 31.25 x 32 = 1000 ml = 1 L 
 
50% inhibition ended in a dilution up to 16 times. 
16 x 7.81 = 125 ml  1 g PYLOS is effective in 125 ml 
32 g PYLOS used gives 125 x 32 = 4000 ml = 4 L 
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The product with maximal concentration has 100% inhibition against H. pylori adhesion in a 
volume up to 1 L and 50% inhibition in a volume up to 4 L. 
 
Table 6 The table shows an example of an evaluation used when grading the rate of agglutination in the microscope 
2-fold dilution  
Dilution 0 2 4 8 16 32 64 128 256 512 
Well 1 2 3 4 5 6 7 8 9 10 
A C.1 PYLOS - - - - - +/- + ++ +++ 
B Prod3 max4 - - + ++ +++ ++++ ++++ ++++ ++++ 
C Prod3 med5 - + ++ +++ ++++ ++++ ++++ ++++ ++++ 
D Prod3 min6 + ++ +++ ++++ ++++ ++++ ++++ ++++ ++++ 
1C. = Control, 3Prod. = Product, 4Max = Maximal concentration, 5Med = Medium concentration, 6Min = Minimal 
concentration, “-“= No growth (100% inhibition), “+” = Weak growth, “++” = Partial growth (50% inhibition),  
“+++” = Strong growth, “++++” = Total growth, (no inhibition) 
 
Treatment of controls 
The controls had a higher concentration of PYLOS than the products. Therefore the activities 
of the controls had to be re-calculated to be comparable with the activities of the analyzed 
products. The dilution, in which the inhibition effect of the product decreased, was divided by 
the regulation factor. The regulation factor is the ratio between the concentration of PYLOS 
in the control and the concentration of PYLOS in the product. 
 
The effect of the controls has been calculated as in the following example where PYLOS 
substrate N+V is used; 
Rosehip extract (N = 0.1 g/ml) and walnut extract (V = 0.3 g/ml) were mixed to a 
concentration ratio of 1:1 with the total amount of 32 g (maximal concentration of PYLOS). 
 24.7 g (N) + 7.4 g (V) in 96 ml = 32 g PYLOS in 96 ml 
32 g / 96 ml = 1 g in 3 ml 
 
The control was 100% effective up to a dilution of 32 times. According to Table 7, the 
regulation factor of N+V at maximal concentration of PYLOS is 2.58. 
32 / 2.58 = 12.4 
12.4 x 3 = 37.2 ml  1 g PYLOS was 100% effective in 37.2 ml 
32 g used gives 37.2 x 32 = 1190 ml ~ 1.2 L 
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The control gave 50% inhibition up to a dilution of 256 times. 
256 / 2.58 = 99.2 
99.2 x 3 = 297.7 ml  1 g PYLOS was 50% effective in 297.7 ml 
32 g used gives 297.7 x 32 = 9526 ml ~ 9.5 L 
The control has 100% inhibition against H. pylori adhesion in a volume up to 1.2 L and 50% 
inhibition up to 9.5 L.  
 
Table 7 Products with PYLOS substrate N+V. The regulation factor is the ratio between concentration of control and 
concentration of product 
g PYLOS/ 
ml product 
Conc. of PYLOS 
in the product (g/ml) 
Conc. of PYLOS  
in the control (g/ml) 
Regulation  
factor  
16+16/250 0.128 0.33 2.58 
8+8/250 0.064 0.33 5.16 
4+4/250 0.032 0.33 10.31 
2+2/250 0.016 0.33 20.63 
7Conc = Concentration 
Table 8 Products with PYLOS substrate N+FV. The regulation factor is the ratio between concentration of control and 
concentration of product 
g PYLOS/  
ml product 
Conc. of PYLOS 
in the product (g/ml) 
Conc. of PYLOS 
in the control (g/ml) 
Regulation  
factor 
16+3.2/250 0.077 0.167 2.17 
8+1.6/250 0.038 0.167 4.35 
4+0.8/250 0.019 0.167 8.70 
2+0.4/250 0.01 0.167 17.40 
7Conc = Concentration 
19 
 
4. RESULTS 
4.1. Product development 
4.1.1. Juices N + V 
 
The pH of these products was between 3.45 and 4. The addition of PYLOS substrate 
increased the pH of the product linearly. The juice products D and E had a lower pH where 
juice E had the lowest.  The temperatures of the juices were measured to 17-23°C at the time 
of tasting.  
In the products with maximal dose of N+V, the rosehip was difficult to dissolve. It floated on 
the surface, got clumpy and required a lot of mixing. The solubility of the powder increased 
with less powder added. The viscosity was high in the products with maximal concentration 
and decreased with lower concentration.  
The walnut powder caused problems with the consistency of the product. Due to its high fat 
content, big particles float on the surface and gave an unattractive sedimentation layer. The 
big particles were also noticeable when drinking the juice. They gave an unpleasant mouth 
feel and tasted very bitter when chewed. The bitterness of the walnut was more palpable at 
higher concentrations and decreased with lower amount added. Some of the juices hid the 
bitter taste even at higher concentrations, i.e. juice B and E.  
The colour of the products did also change with the concentration of PYLOS substrate. At 
maximal concentration the walnut had a strong influence of the colour and many of the juices 
turned in to brown. That colour was not attractive in juices, which were normally light orange 
coloured. Their appearances were also thick, brown and opaque. In juice E, the purple colour 
hid the discoloration of the walnut. The juices having the best ratings in this test were juice E 
and B. Table 9 shows the results of the descriptive sensory test of the juices containing 
PYLOS substrate N+V. Bitterness is graded in a 4-degree scale where 4 is most bitter. The 
general score is graded at a 4-degree scale where 4 are the highest score. Highest acceptable 
concentration is marked with an “x”. 
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Table 9 The table shows the results from the product development of juices containing PYLOS substrate N+V 
Juice 
 
Conc7  
(N+V)g 
Colour 
 
Prominent taste 
 
Bitterness  
(1-4) 
General  
Score (1-4) 
        
  A 16+16 Orange/brown/yellow Rosehip/walnut 3 1 
A 8+8 Yellow/Orange/brown Walnut/M.c.10 3 2 
A 4+4 Yellow/Orange/ brown M.c.10/Rosehip 1 3 
A 2+2 Yellow/Orange M.c.10 1 4          x12 
      B  16+16 Orange/light brown S.m.c.11/walnut 3 2 
B 8+8 Orange/light brown/yellow S.m.c.11/rosehip 2 3 
B 4+4 Yellow/Orange/ brown S.m.c.11 1 4          x12 
B 2+2 Yellow/Orange S.m.c.11 1 4 
      C 16+16 Brown/Orange Walnut/rosehip 4 1 
C 8+8 Light brown/Orange Walnut/rosehip 4 2 
C 4+4 Orange/brown M.c.10/rosehip 3 3 
C 2+2 Yellow/Orange M.c.10/rosehip 2 3          x12 
      D 16+16 Dark brown Walnut/rosehip 4 1 
D 8+8 Brown M.c.10 3 2 
D 4+4 Light brown M.c.10 3 3 
D 2+2 Light brown M.c.10 2 3         x12 
      E 16+16 Dark purple  M.c.10/rosehip 2 2 
E 8+8 Purple M.c.10 2 3          x12 
E 4+4 Purple M.c.10 1 4 
E 2+2 Purple M.c.10 1 4 
      F  16+16 Brown Walnut/apple 4 1 
F 8+8 Light brown/yellow M.c.10/walnut 3 2 
F 4+4 Yellow/grey/uncolored M.c.10/S.m.c.11 1 3          x12 
F 2+2 Yellow/grey/uncolored M.c.10/S.m.c.11 1 4 
7Conc. = Concentration, 10M.c. = Main component of the product, 11S.m.c = Second main component of the product  
12x = Highest acceptable concentration 
 
4.1.2. Juices N + FV 
 
The pH of these products was between 3.25 and 3.58. The addition of PYLOS substrate 
increased the pH of the product linearly as for the juices with N+V. The juices D and E had a 
low pH where juice E had the lowest. The temperature of the juices was 17-23°C at the time 
of tasting.  
In products containing N+FV, the rosehip was difficult to dissolve, but in these products the 
freeze dried walnut was even harder to dissolve and were visualized as brown spots in the 
juice. The freeze dried walnut extract did also float on the surface, but was not visible in the 
21 
 
same extent as the walnut powder. The juice product C, with highest concentrations of 
PYLOS substrate was heated to 48°C for 10 s which facilitated the solubility and made the 
character smoother and planer. Using a homogenizer did also facilitate the solubility. No 
sedimentation was caused by the freeze dried walnut extract. The bitter taste was less 
significant using the walnut extract compared with the walnut powder and the bitterness 
decreased with the lower amount added or by warming the juice. It was also noticed that 
some product flavors hid the bitterness more than others. Adding the PYLOS substrate N+FV 
due to the low amount extract used did not discolour the juices. Table 10 shows the results of 
the descriptive sensory tests of the product development procedure of the juices containing 
PYLOS substrate N+FV. 
Table 10 The table shows the results from the product development of juices containing Pylos substrate N+FV 
Juice 
 
Conc.7  
(N+FV)g 
Colour 
 
Prominent taste 
 
Bitterness  
(1-4) 
General score  
(1-4) 
        
  A 16+3.2 Orange/brown/yellow Rosehip/walnut 4 1 
A  8+1.6 Yellow/orange Walnut/M.c.10 3 2 
A 4+0.8 Yellow/orange M.c.10/rosehip 1 3          x12 
A 2+0.4 Yellow/orange M.c.10 1 4 
      B 16+3.2 Orange/light brown S.m.c.11/walnut 3 1 
B 8+1.6 Orange/yellow/brown S.m.c.11/rosehip 2 2 
B 4+0.8 Orange/yellow S.m.c.11 1 3          x12 
B 2+0.4 Yellow/orange S.m.c.11 1 4 
      C 16+3.2 Brown/orange Walnut/rosehip 4 2 
C (h)13 16+3.2 Brown/orange M.c.10/walnut 2 2 
C 8+1.6 Light brown/orange Walnut/rosehip 3 3 
C (h)13 8+1.6 Light brown/orange Walnut/rosehip 1 3          x12 
C 4+0.8 Yellow/orange M.c.10/walnut 2 4 
C 2+0.4 Yellow/orange M.c.10/rosehip 1 3 
      D 16+3.2 Dark brown Walnut/rosehip 4 1 
D 8+1.6 Brown M.c.10 3 2 
D 4+0.8 Light brown M.c.10 2 3         x12 
D 2+0.4 Light brown M.c.10 2 4 
      E  16+3.2 Dark purple  M.c.10/rosehip 2 2 
E 8+1.6 Purple M.c.10/S.m.c.11 1 3         x12 
E 4+0.8 Purple M.c.10/S.m.c.11 1 4 
E 2+0.4 Purple M.c.10/S.m.c.11 1 4 
7Conc = Concentration, 10M.c. = Main component of the product, 11S.m.c. = Second main component of the product,  
12x = Highest acceptable concentration, 13(h) = Heated at 48°C for 10s 
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4.1.3. Fermented milk products N + V 
 
The different fermented products had varying pH between 4.22-4.55 with product J at the 
lowest. The addition of PYLOS substrate increased the pH linearly as for the juice products. 
The temperature of the products was measured to 20-21°C at the time of tasting. 
The products tested had natural taste and almost the same fat content, which made the results 
of the sensory tests similar. The rosehip powder was difficult to dissolve, but was not 
experienced as clumping due to the thicker consistency of the fermented product. The 
viscosity increased when adding the PYLOS substrate, but did not get too thick thanks to the 
low fat content. The consistencies were regarded as pleasant and were considered as best in 
higher concentrations. The products were comparable with a between meal-snack, i.e. 
PYLOS substrate was a good substitute for muesli. The particles did not give an unpleasant 
mouth feel, as the juices containing N+V. On the contrary, the particles increased the tasting 
experience of the product. 
The colour of the products was only changed slightly orange with increasing concentration of 
PYLOS. However, the colour change was not a disadvantage for the appearances of the 
products. At lower concentrations, the PYLOS substrate was just visualized as orange and 
brown spots in the white product.  
Flavours of both rosehip and walnut could be recognized in the products at higher 
concentrations, but the fermented milks hid all taste of bitterness. The addition of PYLOS did 
actually increase the overall impression of the product and regarding the general score (Table 
11), the products with higher concentrations of PYLOS were generally better than those with 
lower concentration. The product J got the lowest general score in the sensory test, since the 
sour taste did not match the taste of walnut properly.  
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Table 11 The table shows results from the product development of fermented milk products containing PYLOS substrate 
N+V 
Fermented 
milk 
Conc. 
(N+V)g 
Colour 
 
Prominent taste 
 
Bitterness  
(1-4) 
General score  
(1-4) 
      G 16+16 W13/orange/light brown Walnut/rosehip 1 3          x 
G 8+8 W13/orange/light brown Rosehip/walnut 1 4 
G 4+4 W13/orange/brown spots M.c.10 1 2 
G 2+2 W13/orange/brown spots M.c.10 1 1 
      H 16+16 W13/orange/light brown Walnut/rosehip 1 3           x 
H 8+8 W13/orange/light brown Rosehip/walnut 1 4 
H 4+4 W13/orange/brown spots M.c.10 1 2 
H 2+2 W13/orange/brown spots M.c.10 1 1 
      I 16+16 W13/orange/light brown Walnut/rosehip 1 3            x 
I 8+8 W13/orange/light brown Rosehip/walnut 1 4 
I 4+4 W13/orange/brown spots M.c.10 1 2 
I 2+2 W13/orange/brown spots M.c.10 1 1 
      J 16+16 W13/orange/light brown M.c.10/walnut/rosehip 1 2 
J 8+8 W13/orange/light brown M.c.10/walnut/rosehip 1 3 
J 4+4 W13/orange/brown spots M.c.10 1 3            x 
J 2+2 W13/orange/brown spots M.c.10 1 3 
10M.c. = Main component of the product, x12 = Highest acceptable concentration, W13 = White 
 
4.2. Verifying microbiological analyses 
4.2.1. Hemagglutination inhibition assay 
 
All products were analyzed with two different bacterial strains, H. pylori CCUG 17874 (74) 
and J99 (99). In the Tables 12-14, the volume in which the product inhibits the bacteria is 
shown as an interval of two different volumes. The first value corresponds to the effective 
volume for H. pylori 74 and the second volume corresponds to the effective volume for H. 
pylori J99. H. pylori 74 are know to have a stronger agglutination than J99 (Miller-Podraza, 
2011). This means that the inhibition was less effective for H. pylori 74 and the inhibition 
volume was lower. In an inhibition volume between e.g. 4000-8000 ml, the bacterial strain 74 
was effective in the volume of 4000 ml and the bacterial strain 99 inhibited in 8000 ml. The 
general inhibition volume could be considered as somewhere between these values. If only 
one volume is shown, the effective volumes were the same for both bacterial strains. 
Juices N+V 
When analyzing the agglutination effect, the juices A, B and C had similar results (Table 12). 
The products with maximal concentration of PYLOS had 100% inhibition diluted to a 
volume of 1 L. In comparison with the control, which had a corresponding effect in 1.2-2.3 L, 
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they were less effective. The control did also have 50% inhibition at a bigger volume than the 
juices. 
The agglutination effect was significant higher in juice D and E. At 100% inhibition, the juice 
D, with maximal concentration was effective in 4-8 L in comparison to the control that was 
effective in 1.1-2.3 L. At 50% inhibition, the juice was effective in 32-64 L and the control in 
19-38 L. The juice E with maximal concentration of PYLOS had 100% inhibition effect in a 
volume of 8-16 L and a 50% inhibition in 32-128 L. The activity of the control was 
unfortunately very low in this experiment and the difference between the product and control 
should probably not be as big as the results showed. 
The agglutination effect against H. pylori was decreasing with decreasing amount PYLOS 
added. At the half concentration (8 + 8 g), the inhibition was effective in about half the 
volume. The difference was expressed in either 100% inhibition, in 50% inhibition or in both 
columns. At a quarter of the concentration (4 + 4 g), the effective volume was shown to be a 
quarter of the volume for maximal concentration, etc. 
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Table 12 The table shows results from the hemagglutination assay of juices with PYLOS substrate N+V 
Juice 
(250ml) 
 
PYLOS  
substrate 
N+V (g) 
100% inhib.15 
Sample (ml)  
Hp.8 74 - 99 
100% inhib.15 
Control (ml) 
Hp.8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp.874-99 
> 50% inhib.15 
Control (ml)  
Hp.8 74-99 
A 16+16 1000 1150-2300 4000 19000-38100 
A 8+8 500 550-1150 2000 9500-19000 
A 4+4 250 300-550 1000 4800-9600 
A 2+2 <250 100-300 1000 2300-4700 
      B 16+16 1000 1150 4000-8000 1150-9500 
B 8+8 500 550 2000-4000 550-4700 
B 4+4 250 300 1000-2000 300-2400 
B 2+2 <250 <100 1000 100-1150 
      C 16+16 1000 1150-2300 4000 19000-38100 
C 8+8 500-1000 550-1150 2000 9500-19000 
C 4+4 250 300-550 1000 4800-9600 
C 2+2 <250 100-300 1000 2300-4700 
      D 16+16 4000-8000 1150-2300 32000-64000 19000-38100 
D 8+8 4000 550-1150 16000-32000 9500-19000 
D 4+4 2000-4000 300-550 8000-16000 4800-9600 
D 2+2 2000 100-300 4000-16000 2300-4700 
      E 16+16 8000-16000 1150 32000-128000 9500-4700 
E 8+8 4000-16000 550 32000-64000 4700-2300 
E 4+4 4000-8000 300 16000-64000 2400-1150 
E 2+2 2000-8000 <100 8000-32000 1150-550 
      F 16+16 2000-8000 1150 16000-32000 2300 
F 8+8 2000-8000 550 8000-16000 1150 
F 4+4 1000-8000 300 4000-16000 550 
F 2+2 1000-8000 <100 4000-8000 300 
Hp8 = H. pylori, Inhib.15 = Inhibiting 
Juices N+FV 
The juice A, B and C containing N+FV with maximal concentration of PYLOS showed at 
least twice as high anti-agglutination effect as the same juices with N+V added (Table 13). 
Inhibition of 100% efficiency was observed in a volume of 2-8 L and 50% inhibition was 
observed between 4-256 L. H. pylori 99 is as mentioned before, known to have a weaker 
agglutination activity.  
The juice product D had 100% inhibition in a volume of 8-32 L in comparison to 3.4-13.5 L 
in the control. The 50% inhibition was shown in 256-512 L, a volume as big as 1-2 bathtubs, 
in comparison with the control that was effective in 27-54 L. The activity was decreasing 
exponentially with lower amount of PYLOS added. The control used in comparison with 
product E was unfortunately lower than normal. 
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Table 13 The table shows results from the hemagglutination assay of juices with Pylos substrate N+FV 
Juice 
(250ml) 
 
PYLOS  
substrate 
N+FV (g) 
100% inhib.15 
Sample (ml) 
Hp.8 74-99 
100% inhib.15  
Control (ml) 
Hp.8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp.8 74-99 
> 50% inhib.15 
 Control (ml) 
Hp.8 74-99 
A 16+3.2 2000-8000 3350-13450 4000-256000 13450-54150 
A 8+1.6 1000-4000 1600-6650 2000-128000 13450-27000 
A 4+0.8 500-2000 350-800 2000-8000 3350-13450 
A 2+0.4 500-1000 100-350 1000-4000 1600-6650 
      B 16+3.2 2000-8000 3350-13450 8000-256000 27000-54150 
B 8+1.6 1000-4000 1600-6650 8000-128000 13450-27000 
B 4+0.8 500-2000 350-800 2000-8000 3350-13450 
B 2+0.4 500-500 100-350 1000-4000 1600-6650 
      C 16+3.2 2000-8000 3350-13450 16000-256000 13450-54150 
C 8+1.6 2000-2000 1600-6650 4000-128000 6650-27000 
C 4+0.8 1000-1000 350-800 2000-8000 3350-13450 
C 2+0.4 1000-500 100-350 1000-4000 1600-6650 
      D 16+3.2 8000-32000 3350-13450 256000-512000 27000-54150 
D 8+1.6 4000-16000 1600-6650 128000-256000 13450-27000 
D 4+0.8 2000-4000 350-350 8000-16000 3350 
D 2+0.4 1000-2000 <100-100 2000-8000 1600 
      E 16+3.2 16000-32000 1600-3350 32000-256000 13450-54150 
E 8+1.6 8000-16000 800-1600 32000-128000 6650-27000 
E 4+0.8 2000-1000 350 8000 800 
E 2+0.4 1000-1000 <100 4000-2000 350 
Hp8 = H. pylori, Inhib.15 = Inhibiting 
 
Fermented milk products, N+V 
The agglutination activity of the fermented milk products was very much lower than in the 
juice products (Table 14). Volumes below 250 ml (<250) means that the product was not 
effective in the dilution 1:1. The volume in which the fermented milk product H with the 
maximal concentration acts 100% inhibitive was 0.5-1 L in comparison to 2.3 L in the 
control. The volume in where the product was 50% effective was not bigger than the 100% 
volume. The agglutination of H. pylori had started already in the dilution 1:2. Product J was 
shown to have the best results of the fermented milk products with a 50% inhibition in 2-8 L. 
The fermented milk products had about half the activity as the juice products A, B and C with 
the same PYLOS substrate N+V.  
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Table 14 The table shows the results from the hemagglutination assay of fermented milk products with PYLOS substrate 
N+V 
Fermented milk 
(250ml) 
 
PYLOS  
substrate 
N+V (g) 
100% inhib.15 
Sample (ml) 
Hp.8 74-99 
100% inhib.15 
Control (ml) 
Hp.8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp.8 74-99 
> 50% inhib.15 
 Control (ml) 
Hp.8 74-99 
G 16+16 500 2300 2000 9500 
G 8+8 500 1150 1000 4700 
G 4+4 250 550 1000-500 2400 
G 2+2 <250 300 500 1150 
      H 16+16 500-1000 2300 1000-500 9500-38100 
H 8+8 500 550 500 4700-19000 
H 4+4 500-250 300 500 2400-9600 
H 2+2 250 100 500 1150-4700 
      I 16+16 500 1150 1000 9500-38100 
I 8+8 500-250 550 1000-500 4700-19000 
I 4+4 250 300-550 500 4800 
I 2+2 <250 100-300 500 2300 
      J 16+16 500-1000 1150-2300 2000-8000 4700-19000 
J 8+8 500 550-1150 500 9500 
J 4+4 250 300-550 500 4800 
J 2+2 <250 100-300 500 2300 
Hp8 = H. pylori, Inhib.15 = Inhibiting 
 
Investigative tests of fermented milk products 
When performing the investigating test with product H (PYLOS; 16 g + 16 g) it was 
observed that the use of different filter papers, incubation times, dilutions and other technical 
aspects in the procedure had little impact on the anti-agglutination effect (Table 15). The 
inhibition volume was found to be the same or very similar as the control (the first product H 
made). When using centrifugation instead of filtration or no extraction at all, the activity 
increased. However, the big particles present made the sample difficult to analyze and the 
result has been considered as less reliable. When adding erythrocytes directly into product H, 
no agglutination occurred, but when adding H. pylori to the mixture, agglutination occurred 
very quickly. 
The chemical test that actually resulted in an increased inhibition effect was when adding 
HCl to the product. The milk proteins caseins, denaturize already at pH 4.6 and could easily 
be discarded through centrifugation. The product was then neutralized with NaOH before 
analyze. The 100% effective inhibition of H. pylori increased from 0.5 L to 1 L and the 
volume in which the product is 50% inhibition increased from 1 L to 4 L. No impact from 
NaCl was observed on the erythrocytes. 
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Table 15 The table shows the results from the hemagglutination assay of the investigation tests of product H 
Method 
(Product H, 250ml) 
 
PYLOS  
substrate 
N+V (g) 
100% inhib.15 
Sample (ml) 
Hp8 74 
100% inhib.15  
Control (ml) 
Hp8 74 
> 50% inhib.15 
Sample (ml)  
Hp8 74 
> 50% inhib.15 
Control (ml) 
Hp8 74 
Product H, 0.5%  16+16 500 500 1000 1000 
Product H, 0.5% (new test) 16+16 500 500 500 1000 
Filter (113 µm) 16+16 500 500 500 1000 
Filter (thick) 16+16 500 500 1000 1000 
Filter (thinn) 16+16 500 500 1000 1000 
Centrifugation (3x4.0 rpm) 16+16 250 500 2000 1000 
Dilut 2 times, 4h (thinn filter) 16+16 1000 500 1000 1000 
Dilut. 2 times extr. over night 16+16 1000 500 1000 1000 
Not extracted 16+16 250 500 2000 1000 
Exp 1:1 Change of conc. 16+16 500 500 500 1000 
Exp 1:2 Change of conc. 8+8 250 500 500 1000 
Exp 1:3 Change of conc. 4+4 <250 500 250 1000 
Exp 2:1 Incub. time, 0.5 h 16+16 500 500 500 1000 
Exp 2:2 Incub. time, 4 h 16+16 250 500 500 1000 
Exp 2:3 Incub. time, o.n. 16+16 250 500 500 1000 
3 M HCl added 16+16 1000 500 4000 1000 
7Conc = Concentration, 8Hp = H. pylori, 16Incub. time = Incubation time, 17o.n. = Over night, 18extr = extracted,  
20Exp = Experiment 
 
Heat treatment 
Heat treatment at 72°C for 15 s of milk with the PYLOS substrate N+V was shown to have a 
small negative effect on the 100% adhesion inhibition against H. pylori. The treatment 
showed a small negative impact of 50% inhibition observing H. pylori strain 74, but did not 
affect the inhibition against strain 99. The same temperature treatment of milk with substrate 
N+FV had a small negative effect of the 100% inhibition of strain 74, but did not affect the 
inhibition of strain 99. No effect was observed at the volume of 50% inhibition (Table 16). 
Heat treatment at 85°C for 5 s of milk with the PYLOS substrate N+V had a negative effect 
of the 100% inhibition of H. pylori strain 74, but did not affect the inhibition of strain 99. The 
heat treatment reduced the volume of 50% inhibition to the half. Heat treatment at 85°C of 
milk with the PYLOS substrate N+FV affected the inhibition of H. pylori strain 74 
negatively, but did not affect the inhibition of strain 99. The heat treatment did not affect the 
50% inhibition volume.   
Milk with substrate N+V actually got an improved 100% inhibition effect after heat treatment 
at 95°C for 10 min. At 50 % inhibition, the heat treatment had a negative effect on inhibition 
of strain 74, but did not affect the inhibition of strain 99. The result was similar for the milk 
with N+FV substrate; the 100% inhibition was improved by the heat treatment. The 50% 
inhibition was negatively affected observing strain 74, but did not change the inhibition 
against strain 99.  
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The juice C containing N+V was not observed to have changes caused by heat treatment on 
the 100% inhibition volume. The volume of 50% inhibition was not changed observing strain 
74, but decreased for strain 99. The inhibition activity in the juice containing N+FV was not 
observed to be affected by the heat treatment.  
Table 16 The table shows the results of the hemagglutination assay of the heat treated products 
Product  
and heat treatment 
(250 ml) 
PYLOS  
substrate 
 
PYLOS 
substrate 
(g) 
100% inhib.15 
Sample (ml) 
Hp8 74-99 
100% inhib.15  
Control (ml) 
Hp8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp8 74-99 
> 50% inhib.15  
Control (ml) 
Hp8 74-99 
Milk, 72°C, 15 s N+V 16+16 <250 250 500-1000 1000 
Milk, 85°C, 5 s N+V 16+16 <250-250 250 500 1000 
Milk, 95°C, 10 min N+V 16+16 500 250 500-1000 1000 
       Milk, 72°C, 15 s N+FV 16+16 <250-250 250 500 500 
Milk, 85°C, 5 s N+FV 16+16 <250-250 250 500 500 
Milk, 95°C, 10 min N+FV 16+16 250-500 250 500-1000 500 
       Juice C, 90°C, 10 s N+V 16+16 1000-2000 1000-2000 8000-4000 8000 
Juice C, 90°C, 10 s N+FV 16+16 2000 2000 16000-8000 16000-8000 
8Hp = H. pylori, 15Inhib = Inhibition 
 
4.2.2. Growth assay 
 
The growth assay was performed on a limited number of products. Table 17-19 shows the 
volume in which the product with maximal concentration of PYLOS substrate inhibits H. 
pylori growth.  
Juices N+V 
The inhibition of H. pylori growth (Table 17) was less effective compared to the inhibition 
against bacterial adhesion which was observed in the hemagglutination assay. The juice 
products A, B and C had similar 100% inhibition activity, a volume that was less than half as 
big as for the control. The effective volume for 50% inhibition almost corresponded to the 
control. The juice products D and E almost corresponded to the controls for 100% inhibition 
and showed a higher efficiency than the controls for 50% inhibition. 
Table 17 The table shows the results of the growth assay of juices containing PYLOS substrate N+V 
Juice 
(250 ml) 
 
PYLOS 
substrate 
N+V (g) 
100% inhib.15 
Sample (ml) 
Hp8 74-99 
100% inhib.15  
Control (ml) 
Hp8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp8 74-99 
> 50% inhib.15  
Control (ml) 
Hp8 74-99 
A 16+16 250 550 1000 1150 
B 16+16 250 550 1000 1150 
C 16+16 250 550 1000 1150 
D 16+16 500 550 2000 1150 
E 16+16 500 550 2000 1150 
8Hp = H. pylori, 15Inhib. = Inhibition 
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Juices N+FV 
The juices with PYLOS substrate N+FV were less effective than juices containing N+V 
(Table 18). The juices containing N+FV did not reach the 100% inhibition level of the 
controls.  The juice D was the only product with 100% inhibition at the dilution 1:1, against 
H. pylori. The volume for inhibition did not differ between the bacterial strains 74 and 99. 
Juice D and E reached a higher 50% inhibition volume than their controls. 
Table 18 The table shows the results from the growth assay of juices containing PYLOS substrate N+FV 
Juice 
(250ml) 
 
PYLOS 
substrate 
N+FV (g) 
100% inhib.15 
Sample (ml) 
Hp8 74-99 
100% inhib.15  
Control (ml) 
Hp8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp8 74-99 
> 50% inhib.15 
Control (ml) 
Hp8 74-99 
A 16+3.2 <250 350 500 800 
B 16+3.2 <250 350 500 800 
C 16+3.2 <250 350 500 800 
D 16+3.2 250 350 1000 800 
E 16+3.2 <250 350 1000 800 
8Hp = H. pylori, 15Inhib. = Inhibition 
 
Fermented milk products 
In the fermented milk products, the activity against H. pylori growth was observed to be less 
than half as effective as the controls (Table 19). No difference could be seen between the 
products. The inhibitory effect in the fermented milk products corresponded to the effect of 
some of the juices with PYLOS substrate N+FV. 
Table 19 The table shows the results of the growth assay of fermented milk products with Pylos substrate N+V 
Fermented milk 
(250ml) 
 
PYLOS 
substrate 
N+V (g) 
100% inhib.15 
Sample (ml) 
Hp8 74-99 
100% inhib.15  
Control (ml) 
Hp8 74-99 
> 50% inhib.15 
Sample (ml) 
Hp8 74-99 
> 50% inhib.15  
Control (ml) 
Hp8 74-99 
G 16+16 <250 550 500 1150 
H  16+16 <250 550 500 1150 
I 16+16 <250 550 500 1150 
J 16+16 <250 550 500 1150 
8Hp = H. pylori, 15Inhib = Inhibition 
 
Heat treatment 
In the heat treated products, no difference could be seen between the products and the 
controls at 100% inhibition (Table 20). At 50% inhibition, milk heat treated at 85°C for 5 s 
and at 95°C for 10 min showed about half the efficiency than the controls. There were no 
difference found between the heat treated juices and the controls.  
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Table 20 The table shows the results of the growth assay of the heat treated products 
Product  
and heat treatment 
(250) 
PYLOS  
Substrate 
 
PYLOS 
Substrate 
(g) 
100% inhib15 
Sample (ml) 
Hp8 74-99 
100% inhib15 
Control (ml) 
Hp8 74-99 
> 50% inhib15 
Sample (ml) 
Hp8 74-99 
> 50% inhib15  
Control (ml) 
Hp8 74-99 
Milk,72°C, 15 s N+V 16+16 <250 <250 1000 1000 
Milk, 85°C, 5 s N+V 16+16 <250 <250 500 1000 
Milk, 95°C,10 s N+V 16+16 <250 <250 500 1000 
       Juice C, 90°C, 10 s N+V 16+16 250-<250 250 1000 1000 
Juice C, 90°C, 10 s N+FV 16+3.2 <250 <250 500 500 
8Hp = H. pylori, 15Inhib. = Inhibition 
 
5. DISCUSSION 
5.1. Product development 
 
The results of the sensory test of the products developed showed that the juices containing 
PYLOS substrate N+FV got the best sensory profiles both in terms of taste and consistency. 
Using FV instead of V decreased the taste of bitterness and also improved the mouth feeling 
and the smoothness of the juice. The walnut substrate was not beneficial for the colour in 
none of the juices, but for juice E, where no colour change was observed. The amount of 
substrate added had a large impact of the taste and consistency. The best general grade was 
found in those juices with lower amounts of PYLOS substrate. Generally there was the 
walnut substrate that caused an odd taste in the products.  
The fermented milk products got good grades in the sensory test. The taste of rosehip and 
walnut fitted well together with the fermented milk and any bitterness was not noticeable. 
The products had a very pleasant consistency and the grades increased with the amount of 
PYLOS added. A potential addition of sugar to the product or the taste of vanilla would 
probably increase the positive eating experience further more.  
 
5.2. Verifying microbiological analyses 
 
The verifying microbiological tests showed that the juice products D and E were highly 
inhibitory against H. pylori. The juices were shown to be more effective than their controls, 
which indicates that the main fruit component in these juices enhance the inhibition effect of 
the PYLOS substrate. Most effective was the juice E with PYLOS substrate N+FV. The 
active chemical component of PYLOS which inhibits H. pylori is not known, but the 
inhibition effect has been reported also from other plants than rosehip and walnut. The 
second main component in juice E has earlier been reported to have activities against the 
bacteria. High molecular weight polysaccharides originating from the seeds of these berries 
have been described to inhibit adhesion of H. pylori to the gastric mucosa in vitro (Galan, et 
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al., 2004). Other fruit and berries have also been shown to have similar effects (Miller-
Podraza, 2009).  
The PYLOS substrate N+FV was shown to have a stronger inhibition effect against bacterial 
adhesion than N+V. This does not support the general view that whole particles of walnut 
would be more effective, due to more components present and no activity loss in the 
extraction stage. A reason could be that the used weight relationship between V and FV was 
not in balance. The freeze dried walnut extract had most likely a higher activity/g than 
presumed. The PYLOS substrate N+V was however more effective against growth of H. 
pylori. In a health perspective, N+V might be more likely to use due to its higher content of 
fatty acids and bigger particles which is present in the stomach for a longer time. 
A problem regarding natural plant products in a functional food aspect is that the components 
and the activity might vary between the seasons. Many factors as weather, cultivation site, 
harvest, degree of maturity and storage conditions can influence the anti-microbial activity of 
the product. Because of this issue, supplier assurance has to be done to declare that the 
activity meets a certain lower limit. 
Treatment of controls 
The controls used were extracts of N+V and N+FV for products with N+V and N+FV, 
respectively. The same control samples were used for all products and were kept in a freezer 
between usages. The effects of the controls varied unfortunately from the beginning of the 
analyzing period to the last usage. In some analyses, the controls had a lower inhibition effect 
than usual. The reason was probably that freezing the control sample several times affected 
the activity negatively. The controls should have been kept frozen in smaller batches to avoid 
the activity loss during several thawing and refreezing procedures.  
Investigation tests of fermented milk products 
When H. pylori attach to cells in the gastric mucosa, interactions occurs between bacterial 
carbohydrate binding proteins, lectins, and glycoconjugates on the surface of the cell. 
Selected sialic acid binding proteins are the group of lectin adhesines that are important in the 
establishment of the colonization in this infection process (Miller-Podraza, 2009). When H. 
pylori was added to the fermented milk products, a rapid agglutination was observed and the 
fermented milk products were shown to be less effective compared to the juice products.  
Milk proteins are separated into caseins and whey proteins. Of the casein proteins, κ-casein 
(kappa-casein) differs from the others. Among others it has two cysteine residues that have 
the possibility to form disulfide bonds. Further, about two thirds of the monomeric molecules 
contain a carbohydrate group which is esterified to one of the threonines amino acids and has 
galactosamine, galactose and one or two sialylated structures containing NeuAc (N-
acetylneuraminic acid) epitopes (Walstra, et al., 2006). Κ-casein is the milk protein that 
contains significant amount of sialic acid (Marier, et al., 2010). It is theoretically possible that 
the presence of sialylated oligosaccharides and sialylated glycoproteins has interfered with 
the hemagglutination-inhibition tests. The sialylated milk compounds thus competed with 
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sialylated saccharides present on erythrocytes resulting in several binding sites for the 
bacteria, which led to faster agglutination and a weaker inhibition effect of PYLOS.  
Centrifugation of a fermented milk product 
In the investigation tests, hydrochloric acid (HCl) was added to one fermented milk product 
to denature the proteins. However the result of this test had been the same without adding 
HCl since the isoelectric point of caseins are about pH 4.6 (Walstra, et al., 2006). In 
fermented milk products, the lactic acid bacteria have lowered the pH to about 4.5 and 
therefore the caseins are uncharged and precipitated. Centrifugation thus removed all caseins 
and the supernatant without κ-casein and sialic acid was neutralized and used for 
hemagglutination. When H. pylori then was added to the product, less extra sialic acid 
bounding sites was present and the inhibition effect of PYLOS was increased. 
Heat treatment 
When milk is heated to 70-90°C, globular proteins as β-lactoglobulin, α-lactalbumin, serum 
albumin and immunoglobulins are denatured. Under that process they exhibit unfolding of 
their peptide chains and mostly lose their biological activity as an enzyme or an antibody and 
become less soluble. When heating, the whey protein β-lactoglobulin exposes a free thiol 
group, which reacts with other disulfide groups and form dimers. Further aggregation may 
occur and trimers and tetramers are produced (Walstra, et al., 2006). In contrast to the whey 
proteins, the caseins proteins are not heat denatured. The denatured serum proteins associate 
with the micelles through disulfide bonds at the casein micelle surface (Andrén, 2011). When 
heating the milk at 95°C for 10 min as in the heat treatment for the process to produce 
fermented products, the ability of H. pylori to attach to the sialic acids on the κ-casein might 
have decreased because of the steric hindrance that appears when the serum proteins are 
covering the micelle surface. The effect of agglutination might therefore have been increased 
and that was also shown via similar results of fermented products and milk heat treated at 
95°C for 10 min.  
The heat treatment of milk inhibited the reaction between H. pylori and the sialic acid 
glycosylated to the κ-casein, but it also seemed to affect the agglutination inhibition of the 
PYLOS substrate negatively. If the results in Table 16 are compared, lower temperatures 
decreased the function of the PYLOS substrate, while heat treatment at higher temperatures 
inhibited the bacterial binding to κ-casein, which resulted in a net positive outcome. Most 
likely a higher temperature also affects PYLOS negatively. The substrate N+V seemed to be 
more sensitive for heat treatment than N+FV. It means that the powder substrate of walnut 
was affected to a greater extent of heat treatment than the freeze dried extract. 
Differences between H. pylori 74 and 99 
The inhibition volume was generally lower for the H. pylori strain 74. That means that this 
strain had a stronger agglutination effect and was less affected by the inhibition substrate. H. 
pylori strain 99 had a weaker agglutination and gave therefore better inhibition results. Both 
strains are however capable to cause infection in the gastric mucosa and the effects of the 
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PYLOS products could be expected to have a practical effect in-between the inhibition 
volumes for H. pylori 74 and H. pylori 99. The inoculation of the bacteria was done with the 
same procedure every day. There is thus an option that the amount of bacteria used might 
have differed among the many analysis performed. 
Method evaluation 
 
The growth assays confirmed the results of the hemagglutination assays. The volume in 
which PYLOS was effective was smaller, but the results showed the same trend. When 
watching the results for the growth assay, it is important to consider that when 200 µl of the 
product with PYLOS substrate was added to the agar gel, an unknown amount was diffusing 
into the gel of 3 ml. The dilution of the product was therefore greater than specified in this 
report, which could explain the lower effective volumes in the results for the growth assays.  
This report showed H. pylori inhibition at 50% as the lowest level. Effects at 25% and 15% 
inhibition were not taken into account and therefore the resolution of the results could have 
been better if lower inhibition effects also were considered. For example, two products with 
different concentrations of PYLOS substrate could have the same effect at 50% inhibition, 
but differ remarkably at 25% inhibition. 
It is also important to consider that these experiments included many technological steps, not 
occurring in the stomach, which could have decreased the product effect. One technical 
aspect decreasing the PYLOS effect was for example the filtration process, where much of 
the substrate was caught in the filter. The active compounds could therefore have been highly 
reduced and not used in the verifying microbiological analysis. Therefore it is likely to 
presume that the inhibition effect of the PYLOS substrate is higher when acting in vivo than 
in vitro. 
The recommended product 
The juice product E with PYLOS substrate N+FV had satisfactory results in both the sensory 
test and the verifying microbiological analyses. The product had a pleasant taste with 
prominent flavors of the main fruit components. The bitterness of walnut was hid to a higher 
extent. The colour was purple and gave the juice a nice visually appealing. The test panel 
accepted the product taste even at higher concentrations of PYLOS substrate.  
In the hemagglutination tests, juice E was shown to have an impressing inhibition effect 
against H. pylori and almost all concentrations tested had better results than the controls, 
which indicated that main components enhanced the effect of PYLOS. A product with 
maximal concentration of PYLOS substrate in a volume of 250 ml was 100% effective 
against H. pylori adhesion in a volume of 16-32 L and 50% effective in 32-256 L. The 
product was 100% effective against H. pylori growth in 0.25 L and 50% effective in 1 L.  
The aim of this future product is not to totally eliminate H. pylori, but to reduce the number 
of bacteria to decrease problems with gastric ulcer and to prevent stomach cancer caused by 
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prolonged infection. There is thus no need to use the maximal concentration of PYLOS 
substrate added.  
6. CONCLUDING REMARKS 
 
The product to be recommended as preferable for addition of the PYLOS substrate, is the 
juice product E with the PYLOS substrate N+FV. 
 
Fermented products are not suitable for this purpose due to the presence of sialylated 
compounds in milk, although fermented products with PYLOS substrate received high scores 
in the sensory test.  
 
To continue this project 
This report have shown which products from the product range of Skånemejerier that would 
be preferable to use in the context of including PYLOS to a food product, in purpose to 
inhibit H. pylori.  
To continue this work, the juice product E containing PYLOS substrate N+FV is being 
recommended as a product to analyze further. It would be desirable to get statistical 
significance of the result based on several analyses and statistical calculations. To see the 
practical use of this food in a new clinical study would also be interesting for further 
knowledge and one step towards product integration to the market of functional foods.  
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